tldrdaily.news logo

FDA Approves Multiple New Options for Opioid Use Disorder Treatment and Overdose Reversal

1 min read
Source: FDA.gov
FDA Approves Multiple New Options for Opioid Use Disorder Treatment and Overdose Reversal
Photo: FDA.gov
TL;DR Summary

The FDA has approved Brixadi, a new buprenorphine extended-release injection for subcutaneous use, to treat moderate to severe opioid use disorder. Brixadi is available in weekly and monthly formulations and offers a new option for people in recovery who may benefit from a weekly injection to maintain treatment adherence. The most common adverse reactions include injection-site pain, headache, constipation, nausea, injection-site erythema, itchy skin at the injection site, insomnia, and urinary tract infections. The FDA continues to implement a comprehensive approach to increase options to treat OUD.

Topics:business#buprenorphine#fda#health#opioid-use-disorder#substance-abuse#treatment
Share this article
  1. FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder  FDA.gov
  2. A new nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval  NPR
  3. Analysis | A new opioid overdose antidote to enter the market  The Washington Post
  4. Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder  PR Newswire
  5. Decision made on RX nasal spray for opioid overdoses  WJW FOX 8 News Cleveland

Reading Insights

Total Reads

0

Unique Readers

1

Time Saved

3 min

vs 4 min read

Condensed

88%

729 → 87 words

Want the full story? Read the original article

Read on FDA.gov